Geneva Advisors’s Core Laboratories CLB Stock Holding History

Geneva Advisors’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.05M	Sell	10,355 -225	-2%	-$24.3K	0.02%	355
2017 Q1	$1.22M	Sell	10,580 -150	-1%	-$17.4K	0.02%	310
2016 Q4	$1.29M	Buy	10,730 +2,482	+30%	+$275K	0.03%	278
2016 Q3	$926K	Sell	8,248 -725	-8%	-$83.5K	0.02%	338
2016 Q2	$1.11M	Buy	8,973 +1,053	+13%	+$127K	0.02%	292
2016 Q1	$890K	Buy	7,920 +1,030	+15%	+$107K	0.02%	322
2015 Q4	$749K	Buy	6,890 +900	+15%	+$103K	0.01%	345
2015 Q3	$598K	Buy	5,990 +2,950	+97%	+$321K	0.01%	361
2015 Q2	$347K	Sell	3,040 -120	-4%	-$14.6K	0.01%	497
2015 Q1	$330K	Sell	3,160 -4,692	-60%	-$500K	0.01%	498
2014 Q4	$945K	Sell	7,852 -57,600	-88%	-$7.57M	0.02%	309
2014 Q3	$9.58M	Sell	65,452 -22,122	-25%	-$3.41M	0.18%	96
2014 Q2	$14.6M	Sell	87,574 -25,589	-23%	-$4.55M	0.27%	91
2014 Q1	$22.5M	Buy	113,163 +36,231	+47%	+$6.84M	0.41%	75
2013 Q4	$14.7M	Buy	76,932 +18,542	+32%	+$3.45M	0.27%	84
2013 Q3	$9.88M	Buy	58,390 +19,409	+50%	+$3.01M	0.21%	91
2013 Q2	$5.91M	Buy	+38,981	New	+$5.52M	0.14%	103

Other funds holding CLB

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wedgewood Partners St Louis, Missouri $484M AUM 16.04% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geneva Advisors's CLB Position: Q2 2017 in Review

Geneva Advisors reduced its Core Laboratories (CLB) stake by 2.1% in Q2 2017, selling an estimated $24.3K and leaving 10,355 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #355.

Geneva Advisors first reported a position in CLB in Q2 2013 and has held it in 17 quarters since. The position peaked at $22.5M in Q1 2014. 360 funds tracked by Wall St. Rank hold CLB as of Q2 2017.

Geneva Advisors held 10,355 shares of Core Laboratories worth $1.05M as of Q2 2017.
Geneva Advisors sold 225 Core Laboratories shares in Q2 2017, an estimated $24.3K.
Core Laboratories made up 0.02% of Geneva Advisors's portfolio in Q2 2017, its #355 holding.
Geneva Advisors first reported a position in Core Laboratories in Q2 2013 and has held it in 17 quarters since.
Geneva Advisors's Core Laboratories position peaked at $22.5M in Q1 2014.
360 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.